Safety of purified Vero cell rabies vaccine manufactured in Pakistan: a comparative analysis of intradermal and intramuscular routes

References

• Warrell M, Warrell D. Rabies and other lyssavirus diseases. Lancet. 2004;363(9413):959–969.
   PubMed Web of Science ®Google Scholar
• Salahuddin N, Jamali S, Ibraheem K, et al. Awareness about rabies post exposure prophylaxis in Pakistan among patients and health care workers: results from an Asian rabies expert bureau study. J Coll Physicians Surg Pak. 2011;21(8):491–494.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rabies vaccines and immunoglobulins: WHO position 2019; [cited 2022 August,11]. Available from: https://www.who.int/publications/i/item/WHO-CDS-NTD-NZD-2018.04.
   Google Scholar
• Kulkarni PS, Sapru A, D’costa PM, et al. Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers. Vaccine. 2013;31(24):2719–2722.
   PubMed Web of Science ®Google Scholar
• Sulehri MA, Riaz O, Hussain R. Rabies: a highly fatal but preventable disease. Annals Punjab Med Coll. 2011;5(1):1–6.
   Google Scholar
• Bose A, Munshi R, Tripathy RM, et al. A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes. Vaccine. 2016;34(40):4820–4826.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rabies vaccines: WHO position paper, April 2018 – recommendations. Vaccine. 2018;36(37):5500–5503.
   PubMed Web of Science ®Google Scholar
• Denis M, Knezevic I, Wilde H, et al. An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route. Vaccine. 2019;37:A99–A106.
   PubMed Web of Science ®Google Scholar
• Hu Q, Liu M-Q, Zhu Z-G, et al. Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China. Hum Vaccin Immunother. 2014;10(6):1645–1649.
   PubMed Web of Science ®Google Scholar
• Jaiiaroensup W, Lang J, Thipkong P, et al. Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally (Results of a prospective randomized trial). Vaccine. 1998;16(16):1559–1562.
   PubMed Web of Science ®Google Scholar
• Sari T, Tulek N, Bulut C, et al. Adverse events following rabies post-exposure prophylaxis: a comparative study of two different schedules and two vaccines. Travel Med Infect Dis. 2014;12(6 Pt A):659–666.
   PubMed Web of Science ®Google Scholar
• Bonito RF, Oliveira N, Nishioka S. Adverse reactions associated with a Fuenzalida-Palacios rabies vaccine: a quasi-experimental study. Rev Soc Bras Med Trop. 2004;37(1):7–9.
   PubMedGoogle Scholar
• Peng J, Lu S, Zhu Z, et al. Safety comparison of four types of rabies vaccines in patients with WHO category II animal exposure: an observation based on different age groups. Medicine. 2016;95(47):e5049.
   PubMed Web of Science ®Google Scholar
• Ramezankhani R, Shirzadi MR, Ramezankhani A, et al. A comparative study on the adverse reactions of purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV). Arch Iran Med. 2016;19(7):502–507.
   PubMed Web of Science ®Google Scholar
• Kang Z, Chiang WC, Goh SH, et al. A case of serious adverse reaction following rabies vaccination. Glob Pediatr Health. 2018;5:2333794X18817143.
   PubMedGoogle Scholar
• Recuenco S, Warnock E, Osinubi MO, et al. A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults. Vaccine. 2017;35(34):4315–4320.
   PubMed Web of Science ®Google Scholar
• Liu H, Huang G, Tang Q, et al. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Hum Vaccin. 2011;7(2):220–224.
   PubMed Web of Science ®Google Scholar
• Dane Ş, Timur H. Sex-related differences in tuberculin reaction, free and total concentrations in patients with autoimmune disorders and controls. Int J Neurosci. 2005;115(6):911–916.
   PubMed Web of Science ®Google Scholar
• de Vries ST, Denig P, Ekhart C, et al. Sex differences in adverse drug reactions reported to the national pharmacovigilance centre in The Netherlands: an explorative observational study. Br J Clin Pharmacol. 2019;85(7):1507–1515.
   PubMed Web of Science ®Google Scholar
• Joung K-I, Jung G-W, Park H-H, et al. Gender differences in adverse event reports associated with antidiabetic drugs. Sci Rep. 2020;10(1):1–10.
   PubMed Web of Science ®Google Scholar
• Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug in women. Biol Sex Differ. 2020;11(1):1–14.
   PubMed Web of Science ®Google Scholar
• Wilde H, Chomchey P, Prakongsri S, et al. Adverse effects of equine rabies immune globulin. Vaccine. 1989;7(1):10–11.
   PubMed Web of Science ®Google Scholar
• Chutivongse S, Wilde H, Benjavongkulchai M, et al. Rabies vaccination during pregnancy: effect on 202 women and their infants. Clin Infect Dis. 1995;20(4):818–820.
   PubMed Web of Science ®Google Scholar
• Sehgal S, Bhattacharya D, Bhardwaj M. Clinical evaluation of purified Vero-cell rabies vaccine in patients bitten by rabid animals in India. J Commun Dis. 1994;26(3):139–146.
   PubMedGoogle Scholar
• Suntharasamai P, Chanthavanich P, Warrell M, et al. Purified Vero cell rabies vaccine and human diploid cell strain vaccine: comparison of neutralizing antibody responses to post-exposure regimens. J Hyg. 1986;96(3):483–489.
   PubMedGoogle Scholar
• Suntharasamai P, Warrell D, Looareesuwan S, et al. New purified Vero-cell vaccine prevents rabies in patients bitten by rabid animals. Lancet. 1986;2(8499):129–131.
   PubMed Web of Science ®Google Scholar